Olema Pharmaceuticals, Inc. (OLMA)
| Market Cap | 1.53B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.88M |
| Shares Out | 38.52M |
| EPS (ttm) | -0.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $37.66 |
| Previous Close | $36.41 |
| Change ($) | 1.25 |
| Change (%) | 3.43% |
| Day's Open | 37.01 |
| Day's Range | 32.12 - 38.52 |
| Day's Volume | 180,285 |
| 52-Week Range | 32.11 - 60.27 |
SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, d...
The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sus...
SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Since going public on Nov. 19, shares of Olema Pharmaceuticals Inc.(NASDAQ:OLMA) have soared past the offering price of $19 per share to over $53, giving the San Francisco-based company a mark...
SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
About OLMA
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Ole... [Read more...]
| Industry Biotechnology | IPO Date Nov 19, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol OLMA |
Analyst Forecasts
The average 12-month stock price forecast for OLMA is 60.67, which is an increase of 61.10% from the latest price.